CTI BIOPHARMA CORP (CTI) [Rocket]

In millions, except per share items	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21
	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q
ASSETS
Current assets:
Cash and cash equivalents	30.4	32.0	66.1	96.9	65.4	95.3	71.9	33.1
Short-term investments	49.5	49.6	29.8					4.1
Accounts receivable, net	15.4	10.6	8.2	2.4
Inventories	0.7	1.1	0.7	0.1
Prepaid expenses and other current assets	3.3	3.6	2.6	3.9	2.9	3.8	2.9	2.2
Total current assets	99.4	96.9	107.4	103.3	68.4	99.0	74.8	39.3
Property and equipment, net				0.0	0.2	0.3	0.4	0.7
Intangible assets, net	23.2	23.8	24.3	24.8
Other assets	3.3	2.8	2.9	3.3	3.9	1.9	2.2	2.8
Total assets	125.9	123.5	134.5	131.4	72.4	101.2	77.5	42.8

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable	2.0	2.4	3.1	2.4	3.9	1.8	1.3	1.2
Accrued expenses	29.4	26.6	26.0	47.0	12.7	10.4	8.6	7.3
Current portion of long-term debt	47.9			47.5	47.4	47.2	2.0	3.3
Other current liabilities	1.8	0.8	0.7	1.9	2.7	2.9	3.9	3.8
Total current liabilities	81.1	29.8	29.8	98.9	66.7	62.3	15.8	15.6
Royalty financing obligation	61.1	60.3	59.7	58.6
Other liabilities	1.2	2.4	2.6	1.8	2.0			0.6
Total liabilities	143.5	140.3	139.8	159.4	68.7	62.3	15.8	16.1

Commitments and contingencies (Note 14)
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value per share:
Common stock, $0.001 par value per share:	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Additional paid-in capital	2,501.2	2,484.6	2,480.4	2,435.1	2,429.6	2,427.9	2,426.6	2,371.9
Accumulated other comprehensive loss	0.0	-0.1	-0.1					0.0
Accumulated deficit	-2,518.9	-2,501.4	-2,485.7	-2,463.1	-2,425.9	-2,389.1	-2,364.9	-2,345.3
Total stockholders' (deficit) equity	-17.6	-16.8	-5.3	-27.9	3.8	38.9	61.7	26.7
Total liabilities and stockholders' (deficit) equity	125.9	123.5	134.5	131.4	72.4	101.2	77.5	42.8

Common stock authorized (in shares)